Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension [Phase 3]

View source ↗

Summary

Phase 3 China extension of KEYNOTE-991 assessed pembrolizumab plus enzalutamide plus androgen deprivation therapy vs placebo plus enzalutamide plus ADT in metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Xtandi (enzalutamide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Hormone-Sensitive Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-11-07